RxDoctor Payments Data

Dawn Minyon Sarver, DO

Family Medicine · Mc Murray, PANPI 1033137971

Payments from drug & device makers

$972in general payments, 2019–2025

Across 58 payments — averaging $16.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$225
  • GSK$220
  • Astellas Pharma US Inc$90
  • Amgen$69
  • Novo Nordisk$68
  • Pfizer$37
  • plus $264 from 13 others

What the payments were for

  • Food & beverage$972100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$972 in reported general payments places this provider in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

See all family medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$60,454
Medicare patients
173
Services billed
858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban50$63,769
OzempicSemaglutide24$37,870
XifaxanRifaximin11$33,813
TrulicityDulaglutide18$28,307
JardianceEmpagliflozin18$25,126
JanuviaSitagliptin Phosphate16$12,933
LinzessLinaclotide15$11,860
Breo ElliptaFluticasone/Vilanterol17$10,390
XareltoRivaroxaban18$9,399
Trelegy ElliptaFluticasone/Umeclidin/Vilanter15$9,358
Repatha SureclickEvolocumab12$6,330
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog14$5,663
Budesonide-Formoterol FumarateBudesonide/Formoterol Fumarate29$4,635
Levothyroxine Sodium444$4,031
Atorvastatin Calcium329$2,912

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$37$63,76950 claims
Novo NordiskOzempic$68$37,87024 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$18$33,81311 claims
Lilly USA, LLCTrulicity$25$28,30718 claims
Boehringer IngelheimJardiance$29$25,12618 claims
GSKBreo Ellipta, Trelegy Ellipta$220$19,74732 claims
AbbVieLinzess, Synthroid$225$13,00053 claims
MerckJanuvia$28$12,93316 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 4,967 family medicine providers in Pennsylvania.

Other family medicine in Mc Murray

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →